Guggenheim analyst Seamus Fernandez started Allergan with a Buy rating and $259 price target, citing his view of its sustained leadership in medical aesthetics with Botox, Juvederm, and Coolsculpting and its pipeline, including rapastinel for severe depression and abicipar for wet AMD.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.